Study S001351

A Randomised, Placebo-controlled, Double-blind, Incomplete Cross-over Design Trial to Evaluate the Effects of Liraglutide on Gastric Emptying, Energy Expenditure and Appetite, and to Evaluate Liraglutide Pharmacokinetics in Non-diabetic Obese Subjects

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00978393
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 49
Start: 2009-09-16
Primary completion: 2011-06-08
Lead sponsor: Novo Nordisk A/S
Conditions: Metabolism and Nutrition Disorder; Obesity
Interventions: DRUG:liraglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2008-003228-44; OTHER:U1111-1111-9119; NIH:2008

Registered primary outcomes

Gastric emptying measured as AUC0-300min of paracetamol postprandial concentration profiles during a standardised meal test with intake of 1.5 g paracetamol [after 35 days of treatment]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024592	Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. van Can J, International journal of obesity (2005)	2014	Randomized trial	PMID 23999198 DOI	cites ClinicalTrials.gov:NCT00978393; registry reference RESULT:23999198